Welcome to our dedicated page for Generate Biomedicines SEC filings (Ticker: GENB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Generate Biomedicines's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Generate Biomedicines's regulatory disclosures and financial reporting.
Pioneering Medicines 02, LLC, a major holder of Generate Biomedicines, Inc., reported indirect ownership of 1,562,500 shares of Common Stock. The filing is an initial ownership report, not a new trade, and notes a control chain through various Flagship Pioneering entities with beneficial ownership disclaimed beyond any pecuniary interest.
Generate Biomedicines, Inc. Chief Executive Officer Michael Nally purchased 20,000 shares of common stock in an open-market transaction at $12.00 per share. Following this purchase, he directly owned 572,707 common shares, with additional indirect holdings reported through the MTN 2024 GST Trust and MTN 2024 GRAT.
Vessey Rupert reported acquisition or exercise transactions in this Form 4 filing.
Generate Biomedicines director Rupert Vessey was granted a new stock option award. The Form 4 reports an option over 29,561 shares of Generate Biomedicines, Inc. common stock, held directly. Following this grant, he holds 29,561 derivative securities.
The footnote states that all shares underlying this option will vest in full on February 19, 2027, provided he continues to serve through that vesting date. This is an equity compensation grant rather than an open-market share purchase or sale.
Generate Biomedicines, Inc. Chief People Officer Beth Grous reported two insider transactions. An account held by her spouse bought 300 shares of common stock at $16.00 per share, recorded as indirect ownership. She also received a grant of 114,020 stock options, which vest in forty-eight equal monthly installments starting after February 19, 2026, contingent on continued service.
Generate Biomedicines director Frances Arnold received a stock option grant for 29,561 shares. The option was awarded at an exercise price of $0.00 per share and increases her directly held derivative position to 29,561 options. These options are scheduled to vest in full on February 19, 2027, if she continues serving through that date.
Generate Biomedicines, Inc. Chief Medical Officer Laurie Anne Lee reported an award of stock options covering 42,230 shares on February 26, 2026. These options were granted at an exercise price of $0.00 per share and will vest in 48 equal monthly installments following February 19, 2026, as long as she continues in service.
Generate Biomedicines, Inc. reported that Chief Legal Officer & General Counsel Martin Sean received a grant of stock options covering 190,034 shares on February 26, 2026. The award was recorded as a grant or other acquisition, not an open-market purchase. According to the disclosure, the options vest in 48 equal monthly installments starting after February 19, 2026, and each installment requires his continued service on the relevant vesting date.
Generate Biomedicines director Nancy A. Simonian received a stock option grant for 29,561 shares of common stock at an exercise price of $0.00 per share. According to the filing, the option vests in full on February 19, 2027, subject to her continued service on that vesting date.
Generate Biomedicines, Inc. executive Jason Silvers, President & CFO, reported several equity transactions. On March 2, 2026, accounts for his daughter and son bought a total of 2,000 shares of common stock in open-market purchases at $16.00 per share, reported as indirect ownership.
On February 26, 2026, he also received two grants of stock options. One option covers 295,608 shares, vesting in two equal installments on February 19, 2029 and February 19, 2030. The other covers 274,493 shares, vesting in forty-eight equal monthly installments following February 19, 2026, in each case contingent on continued service.
Generate Biomedicines, Inc. reported multiple insider transactions involving entities affiliated with Flagship Pioneering. On March 2, 2026, shares of Series A, B and C preferred stock held by several Flagship funds automatically converted into common stock on a one-for-1.5190 basis upon the closing of the company’s initial public offering.
On the same date, Flagship Pioneering Fund VII, L.P., FPN II, L.P. and Pioneering Medicines 02, LLC each purchased 1,562,500 shares of common stock at $16.00 per share, totaling 4,687,500 shares, all reported as indirect ownership. Separately, on February 26, 2026, Noubar Afeyan received a stock option for 29,561 shares, vesting in full on February 19, 2027, contingent on continued service.